SCHEMBL6421037

SCHEMBL6421037

CCCOC(OCCC)(OCCC)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.43
KCNN4 O15554 3/20 0.41
MAPK1 P28482 1/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MLNR O43193 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HRH1 P35367 1/20 0.39
OPRM1 P35372 1/20 0.39
DRD3 P35462 1/20 0.39
OPRK1 P41145 1/20 0.39
HTR2B P41595 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39
CACNA1C Q13936 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421194 0.89 LTA4H (0.47) KIF11KCNN4MAPK1ALDH1A1LTA4H
SCHEMBL6415488 0.87 LTA4H (0.47) KIF11MAPK1LMNAMEN1KMT2A
SCHEMBL379267 0.83 KCNN4 (0.43) KIF11KCNN4MAPK1LMNAALDH1A1
SCHEMBL28800774 0.81 KCNN4 (0.41) KIF11KCNN4MAPK1LMNAALDH1A1
SCHEMBL8434800 0.81 KIF11 (0.43) KIF11KCNN4MAPK1LMNAMEN1
SCHEMBL2348691 0.81 KIF11 (0.65) KIF11KCNN4MAPK1LMNAMEN1
SCHEMBL28729169 0.80 LTA4H (0.41) KIF11MAPK1LMNAMEN1KMT2A
SCHEMBL1224411 0.79 MAPK1 (0.56) KIF11KCNN4MAPK1LMNAMEN1
SCHEMBL10786977 0.79 CHRM2 (0.47) KIF11KCNN4MAPK1LMNAMEN1
SCHEMBL724358 0.79 MAPK1 (0.44) KIF11KCNN4MAPK1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240108728-A1 IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME ANHUI UNIVERSITY (CN) 2024-04-04 US claimed
WO-2023221320-A1 IMPROVED LOW-TOXICITY AND HIGHLY EFFICIENT PHARMACEUTICAL EXCIPIENT OF ORTHOESTER MIXTURE, METHOD FOR PREPARING SAME, AND LOCAL SUSTAINED-RELEASE PREPARATION COMPRISING SAME 安徽大学 2023-11-23 WO claimed
US-20240108728-A1 IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME ANHUI UNIVERSITY (CN) 2024-04-04 US disclosed
US-20160280851-A1 IMINOETHER COMPOUND, POLYESTER RESIN COMPOSITION, METHOD FOR PRODUCING CARBOXYLIC ACID ESTER, POLYESTER FILM, BACK SHEET FOR SOLAR CELL MODULE, AND SOLAR CELL MODULE FUJIFILM CORPORATION (JP) 2016-09-29 US disclosed
US-20050003085-A1 Composition for forming a coating film, method of preparing the composition, tantalum oxide film and method of forming the tantalum oxide film JSR CORPORATION (JP) 2005-01-06 US disclosed
US-6806210-B2 MIXTURES OF GROUP V COMPOUNDS AND SOLVENTS, USED TO FORM DIELECTRIC LAYERS ON SILICON SUBSTRATES; HEAT TREATMENT JSR CORPORATION (JP) 2004-10-19 US disclosed
US-20030003235-A1 From reaction product of a tantalum alkoxide and an amino alcohol, polyalcohol, beta-diketone or ketoester, ester of of beta-dicarboxylic acid, lactic acid, ethyl lactate or 1,5-cyclooctadiene or a hydrolyzate of reaction product JSR CORPORATION (JP) 2003-01-02 US disclosed
US-4311782-A POLYETHER OF ORTHOCARBOXYLIC ESTER HOECHST AKTIENGESELLSCHAFT (DE) 1982-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108728-A1 IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME TLR7, PON1, MYD88 KIF11 258/4885KCNN4 3422/4885MAPK1 1473/4885
US-20160280851-A1 IMINOETHER COMPOUND, POLYESTER RESIN COMPOSITION, METHOD FOR PRODUCING CARBOXYLIC ACID ESTER, POLYESTER FILM, BACK SHEET FOR SOLAR CELL MODULE, AND SOLAR CELL MODULE BRS3, RAD1, RAD51 KIF11 4048/4885KCNN4 2974/4885MAPK1 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.